Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Common Equity (2019 - 2025)

Historic Common Equity for Madrigal Pharmaceuticals (MDGL) over the last 14 years, with Q3 2025 value amounting to $625.7 million.

  • Madrigal Pharmaceuticals' Common Equity fell 1948.43% to $625.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $625.7 million, marking a year-over-year decrease of 1948.43%. This contributed to the annual value of $754.4 million for FY2024, which is 8611.44% up from last year.
  • As of Q3 2025, Madrigal Pharmaceuticals' Common Equity stood at $625.7 million, which was down 1948.43% from $696.0 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Common Equity high stood at $857.1 million for Q2 2024, and its period low was $10.7 million during Q3 2022.
  • In the last 5 years, Madrigal Pharmaceuticals' Common Equity had a median value of $260.6 million in 2021 and averaged $387.0 million.
  • As far as peak fluctuations go, Madrigal Pharmaceuticals' Common Equity plummeted by 9545.73% in 2022, and later soared by 339298.84% in 2024.
  • Over the past 5 years, Madrigal Pharmaceuticals' Common Equity (Quarter) stood at $196.1 million in 2021, then rose by 0.65% to $197.4 million in 2022, then surged by 105.35% to $405.3 million in 2023, then soared by 86.11% to $754.4 million in 2024, then decreased by 17.05% to $625.7 million in 2025.
  • Its Common Equity was $625.7 million in Q3 2025, compared to $696.0 million in Q2 2025 and $710.6 million in Q1 2025.